Avid Bioservices, Inc.
Avid Bioservices, Inc. (CDMO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
cdmo · stock forecast · 10 analysts (3M) · FMP · updated Jun 4, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$8.00
Consensus
$8.00
-35.9% upside
Low
$8.00
Median: $8 · Last Close: $12.49
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $12.49 | ↓ 0.03% |
1-day model range: $12.48–$12.49. Peak: $12.49 (-0.03%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $11 | -12.2% |
| 2028 | $10 | -18.1% |
| 2029 | $10 | -21.1% |
| 2030 | $10 | -22.7% |
| 2031 | — | -23.5% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CDMO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-11-07 | RBC Capital | Downgrade ↓ | Outperform→Sector Perform |
| 2024-09-10 | RBC Capital | Maintains | Outperform→Outperform |
| 2024-09-10 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2024-07-03 | RBC Capital | Maintains | Outperform→Outperform |
| 2024-04-30 | RBC Capital | Maintains | Outperform→Outperform |
| 2024-03-11 | Stephens & Co. | Maintains | Overweight→Overweight |
| 2024-03-07 | RBC Capital | Maintains | Outperform→Outperform |
| 2023-12-08 | Craig-Hallum | Maintains | Buy→Buy |
| 2023-12-08 | Keybanc | Maintains | Overweight→Overweight |
| 2023-12-08 | RBC Capital | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Avid Bioservices, Inc. (CDMO) stock. Of the recent 49 rating actions, 7 were upgrades and 6 were downgrades. 10 analysts currently cover CDMO.
Analyst Recommendation Trends
CDMO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$163M
↓ 27.5% YoY
Revenue Next Year
$190M
↑ 16.8% YoY
EPS This Year
$-0.38
EPS Next Year
$-0.11
↓ 70.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast CDMO EPS of $-0.38 for the current fiscal year, based on estimates from 1 analysts. The CDMO revenue forecast is $163M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The CDMO stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus CDMO price target is $8.00 (-35.9% upside), with an analyst consensus of Buy.
The CDMO short-term stock prediction for tomorrow is $12.49 (-0.03%). The CDMO stock price prediction for 2027 estimates an average of $11. The CDMO stock prediction for 2030 projects a range of $10–$10.
Avid Bioservices, Inc. trades on NASDAQ under the ticker CDMO. The CDMO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 90% of covering analysts.
Frequently asked questions
CDMO forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month CDMO price target is $8.00, with a high forecast of $8.00 and a low of $8.00. The median price target is shown in the chart above when available. This implies -35.9% potential upside from the current price of $12.49.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.